Isofol Medical

The information in the press release is intended for investors.

The shareholders in Isofol Medical AB (publ), Reg. No. 556759-8064, with its registered office in Gothenburg, are hereby invited to attend the annual general meeting held on Wednesday, May 21, 2025 at 3 p.m. at Biotech Center, Arvid Wallgrens backe 20, Fl. 5, Gothenburg, Sweden. Registration at the annual general meeting starts at 2:30 p.m. and ends when the meeting convenes.

The complete notice to attend is available in Swedish on the company´s website, www.isofolmedical.com

For further information, please contact
Isofol Medical AB (publ)
Margareta Hagman, CFO
E-mail: margareta.hagman@isofolmedical.com
Telephone: +46 (0)738 73 34 18

The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEST on April 17, 2025.

About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a research-based biotechnology company working to improve the prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is urgent. A phase Ib/II study is now being conducted with a new dosing regimen that is expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
www.isofolmedical.com